Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance

AIDS

Volumn 21, Issue 11, 2007, Pages 1449-1455

  Boffito, Marta ^a   Winston, Alan ^a   Jackson, Akil ^a   Fletcher, Carl ^a   Pozniak, Anton ^a   Nelson, Mark ^a   Moyle, Graeme ^a   Tolowinska, Izabela ^a   Hoetelmans, Richard ^b   Miralles, Diego ^b   Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b TIBOTEC BVBA   (Belgium)

Author keywords

Darunavir; Drug interactions; Etravirine; Investigational antiretroviral drugs

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RASH; TREATMENT DURATION; VIRUS RESISTANCE;

ADULT; ANTI-RETROVIRAL AGENTS; AREA UNDER CURVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 34250854707     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282170ab1     Document Type: Article

References (19)

1. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
2. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al., for the Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
3. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, et al., for the CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39:1038-1046.
4. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-128.
5. Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther 2005; 10:469-477.
6. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC125, a novel next-generation non-nucleoside reverse transcriptase inhibitor active against non-nucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
7. Gruzdev B, Rakhmanova A, Doubovskaya E, Yakovlev A, Peeters M, Rinehart A, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naïve, HIV-1 infected subjects. AIDS 2003; 17:2487-2494.
8. Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, et al. An open-label assessment of TMC125: a new, next-generation NNRTI, for 7 days in HIV-1-infected individuals with NNRTI resistance. AIDS 2003; 17:F49-F54.
9. Montaner J, Domingo P, Junod P, Lazzarin A, Pozniak AL, Tsoukas C, et al. Safety and tolerability of TMC125 in 3-class experienced HIV-infected patients: 24-week primary analysis of trial TMC125-C203. 10th European AIDS Conference. Dublin, November 2005 [abstract LBPS3/7B].
10. Nadler JP, Grossman HA, Hicks C, Shalit P, Jayaweera DT, Thompson M, et al. Efficacy and tolerability of TMC125 in HIV patients with NNRTI and PI resistance at 24 weeks: TMC125-C223. 10th European AIDS Conference. Dublin, November 2005 [abstract LBPS3/7.3].
11. Scholler-Gyure M, Leemans R, Beets G, Vandermeulen K, Peeters M, Baeten B, et al. Effect of food on the oral bioavailability of the phase III formulation of TMC125. 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, April 2006 [abstract 80].
12. Katlama C, Carvalho MI, Cooper D, de Backer K, Lefebvre E, Pedro R, et al. TMC114/r outperforms in investigator selected PI(s) in 3-class-experienced patients: week 24 primary analysis of POWER 1 (TMC 114-C213). Third IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 2005 [abstract WeOaLB0102].
13. Sekar V, Guzman S, Stevens T, DePaepe E, Lefebvre E, Hoetelmans R. Absolute bioavailability of TMC114, administered in the absence and in the presence of low-dose ritonavir. 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, April 2006 [abstract 86].
14. Hoetelmans R, Lefebre E, van der Sandt I, Marien K, de Pauw M, Peeters M, et al. Pharmacokinetics and effect of food on TMC114, a potent next generation PI, boosted with low-dose ritonavir. 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, April 2004 [abstract 39].
15. Sekar V, Kestens D, Guzman S, de Pauw M, de Paepe E, Vangeneugden T, et al. The effects of different meal types on the pharmacokinetics of TMC114 tablet formulation dosed with ritonavir in healthy volunteers. 10th European AIDS Conference. Dublin, November 2005 [abstract PE4.1/1].
16. Vingerhoets J, Peeters M, Corbett C, Iveson K, Vandermeulen K, Keen R, et al. Effect of baseline resistance on the virologic response to a novel NNRTI, TMC125, in patients with extensive NNRTI and PI resistance: analysis of study TMC125-C223. 13th Conference on Retroviruses and Opportunistic Infections. Denver, February 2006 [abstract 154].
17. Sekar V, de Meyer S, Vangeneugden T, Lefebvre E, de Pauw M, van Baelen, et al. Absence of TMC114 exposure-efficacy and exposure-safety relationships in POWER 3. 16th International Conference on AIDS. Toronto, August 2006 [abstract TuPe0078].
18. Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmacokinetic interactions. J Antimicrob Chemother 2005; 56:1-5.
19. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20:795-803.